Actionable news
All posts from Actionable news
Actionable news in UTHR: United Therapeutics Corporation,

UTHR buyout rumors; Lilly LLY succeeds in late-stage migraine trial; CARA SPPI up on earnings

Price and Volume Movers

United Therapeutics Corporation (NASDAQ:UTHR) shares closed up $136.81 following a report in the Evening Standard of a potential acquisition of the company. Gilead Sciences (NASDAQ: GILD) is believed to be a frontrunner with other names in the frame including Novartis (NYSE: NVS) and GlaxoSmithKline PLC (NYSE: GSK).

Eli Lilly and Company (NYSE: LLY) announced that its second Phase 3 trial of lasmiditan (SPARTAN trial), for the acute treatment of migraine, met both its primary and key secondary endpoints. Lilly plans to submit a New Drug Application (NDA) for lasmiditan to the FDA in 2H 2018. Data from SAMURAI, the first of the two pivotal Phase 3 studies, were announced in 2016 under the charge of CoLucid Pharmaceuticals, which was acquired by Lilly in March 2017.

Cara Therapeutics Inc (NASDAQ:CARA) shares surged to close up 23% to $16.34. The company provided a pipeline...